Seragy launches with €12 million financing to advance quantitative biomarkers for neurodegenerative diseases

The Medical News ·
Health & Medicine United Kingdom

seragy holding GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, has secured €12 million in funding to accelerate the development of its SeRAS® platform (Seed Replication, Analysis and Subtyping) and expand its laboratory and analytical capabilities. The financing is backed by Commerzbank, the Mittelständische…

Read original article on The Medical News →

Related news